Evidence map›Paper›PMID 40390040›Full record

ArticleBreast cancer research : BCR2025

Erbin interacts with NHERF1 and Ezrin to stabilize a membrane ErbB2 signaling complex in HER2-positive breast cancer.

Jaekwang Jeong, Kwangmin Yoo, Jongwon Lee, Jae Hun Shin, Jungmin Choi, John Wysolmerski

Abstract read
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jaekwang JeongSection of Endocrinology and Metabolism, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06520, USA. Jaekwang.jeong@yale.edu.
Kwangmin YooDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea.
Jongwon LeeDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea.
Jae Hun ShinIntegrative Science and Engineering Division, Underwood International College, Yonsei University, Incheon, 21983, South Korea.
Jungmin ChoiDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea.
John WysolmerskiSection of Endocrinology and Metabolism, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06520, USA. john.wysolmerski@yale.edu.

Funding

PMCA2 regulates mammary gland involution and breast cancerR01HD076248 · NICHD · YALE UNIVERSITY · PI WYSOLMERSKI, JOHN J · 2014 to 2024
$4.4M
Heterodimerization of the Calcium-sensing receptor with the GabaB receptors in the breast.R01HD100468 · NICHD · YALE UNIVERSITY · PI WYSOLMERSKI, JOHN J · 2020 to 2024
$2.1M
National Research Foundation of Korea NRF2022R1A4A2000827NICHD NIH HHS R01 HD076248NICHD NIH HHS R01 HD100468NIH HHS HD100468
6 · The paper itself

Abstract

Approximately 20% of breast cancers overexpress ErbB2/HER2/Neu, a receptor tyrosine kinase. Our previous studies demonstrated that HER2 interacts with the calcium pump, PMCA2, and the scaffolding molecules, NHERF1 and Ezrin to stabilize HER2/HSP90 interactions and contribute to the retention of active HER2 at the plasma membrane. In the normal mammary epithelium where apical/basal polarity is tightly regulated by junctional proteins, HER2 is expressed at low levels in the basolateral membrane and interacts with the LAP family member, Erbin, whereas PMCA2, NHERF1, and Ezrin localize to the apical membrane. Here, we show that loss of apical membrane polarity in hyperplastic lesions of MMTV-Neu mammary glands or in human DCIS leads to intermixing of these molecules and allows Erbin to interact with NHERF1, Ezrin and HER2 initially within the basolateral membrane and then more diffusely throughout the plasma membrane. In SKBR3 cells, Erbin interacts with NHERF1, Ezrin and HER2 in actin-rich membrane protrusions that we have previously described to be sites of active HER2 signaling. Knockdown of Erbin in these cells reduced HER2 signaling by disrupting the formation of a HER2/NHERF1/Ezrin/HSP90 protein complex in the membrane protrusions. Furthermore, inhibition of Ezrin or knock-down of NHERF1 expression disrupted the ability of Erbin to interact with HER2. Taken together, our data suggest that Erbin supports HER2 stability, HER2 membrane retention and HER2 transforming ability by interacting with Ezrin and NHERF1 to maintain a multi-protein signaling complex necessary for HER2-mediated transformation.

Indexed as

Breast NeoplasmsCytoskeletal ProteinsErb-b2 Receptor Tyrosine KinasesPhosphoproteinsSodium-Hydrogen ExchangersAdaptor Proteins, Signal TransducingAnimalsCell Line, TumorCell MembraneCell PolarityEzrinFemaleHSP90 Heat-Shock ProteinsHumansMiceProtein BindingAdaptor Proteins, Signal TransducingCytoskeletal ProteinsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesERBIN protein, humanEzrinHSP90 Heat-Shock ProteinsPhosphoproteinssodium-hydrogen exchanger regulatory factorSodium-Hydrogen ExchangersApical/basal polarityErbinEzrinHER2HSP90NHERF1

Identifiers

PMID40390040
PMCPMC12090624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.